224 related articles for article (PubMed ID: 24723985)
1. A novel tumor targeting drug carrier for optical imaging and therapy.
Li R; Zheng K; Hu P; Chen Z; Zhou S; Chen J; Yuan C; Chen S; Zheng W; Ma E; Zhang F; Xue J; Chen X; Huang M
Theranostics; 2014; 4(6):642-59. PubMed ID: 24723985
[TBL] [Abstract][Full Text] [Related]
2. A drug carrier targeting murine uPAR for photodynamic therapy and tumor imaging.
Zhou X; Zheng K; Li R; Chen Z; Yuan C; Hu P; Chen J; Xue J; Huang M
Acta Biomater; 2015 Sep; 23():116-126. PubMed ID: 26004218
[TBL] [Abstract][Full Text] [Related]
3. Zinc phthalocyanine conjugated with the amino-terminal fragment of urokinase for tumor-targeting photodynamic therapy.
Chen Z; Xu P; Chen J; Chen H; Hu P; Chen X; Lin L; Huang Y; Zheng K; Zhou S; Li R; Chen S; Liu J; Xue J; Huang M
Acta Biomater; 2014 Oct; 10(10):4257-68. PubMed ID: 24969665
[TBL] [Abstract][Full Text] [Related]
4. Tumor Targeting Chemo- and Photodynamic Therapy Packaged in Albumin for Enhanced Anti-Tumor Efficacy.
Zheng K; Liu H; Liu X; Wang Y; Li L; Li S; Xue J; Huang M
Int J Nanomedicine; 2020; 15():151-167. PubMed ID: 32021171
[TBL] [Abstract][Full Text] [Related]
5. Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo.
Zheng K; Li R; Zhou X; Hu P; Zhang Y; Huang Y; Chen Z; Huang M
Int J Nanomedicine; 2015; 10():5327-42. PubMed ID: 26346331
[TBL] [Abstract][Full Text] [Related]
6. DOT corrected fluorescence molecular tomography using targeted contrast agents for small animal tumor imaging.
Tan Y; Cao Z; Sajja HK; Lipowska M; Wang YA; Yang L; Jiang H
J Xray Sci Technol; 2013; 21(1):43-52. PubMed ID: 23507851
[TBL] [Abstract][Full Text] [Related]
7. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
8. Albumin-based drug carrier targeting urokinase receptor for cancer therapy.
Li H; Wang Z; Yu S; Chen S; Zhou Y; Qu Y; Xu P; Jiang L; Yuan C; Huang M
Int J Pharm; 2023 Mar; 634():122636. PubMed ID: 36696930
[TBL] [Abstract][Full Text] [Related]
9. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
10. A supramolecular nanocarrier for efficient cancer imaging and therapy by targeting at matriptase.
Jiang L; Jiang Y; Li L; Zheng K; Yu S; Li J; Yuan C; Huang M
J Control Release; 2021 Jun; 334():153-163. PubMed ID: 33894302
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle Binding to Urokinase Receptor on Cancer Cell Surface Triggers Nanoparticle Disintegration and Cargo Release.
Li S; Yuan C; Chen J; Chen D; Chen Z; Chen W; Yan S; Hu P; Xue J; Li R; Zheng K; Huang M
Theranostics; 2019; 9(3):884-899. PubMed ID: 30809315
[TBL] [Abstract][Full Text] [Related]
12. Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy.
Zhou Y; Yu S; Chen D; Li H; Xu P; Yuan C; Jiang L; Huang M
Mol Pharm; 2023 Feb; 20(2):905-917. PubMed ID: 36463525
[TBL] [Abstract][Full Text] [Related]
13. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
14. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
15. Apomyoglobin is an efficient carrier for zinc phthalocyanine in photodynamic therapy of tumors.
Cozzolino M; Pesce L; Pezzuoli D; Montali C; Brancaleon L; Cavanna L; Abbruzzetti S; Diaspro A; Bianchini P; Viappiani C
Biophys Chem; 2019 Oct; 253():106228. PubMed ID: 31349136
[TBL] [Abstract][Full Text] [Related]
16. uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection.
Yang L; Sajja HK; Cao Z; Qian W; Bender L; Marcus AI; Lipowska M; Wood WC; Wang YA
Theranostics; 2013; 4(1):106-18. PubMed ID: 24396518
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo anti-tumor effect of Trichobakin fused with urokinase-type plasminogen activator ATF-TBK.
Pham DD; Pham TH; Bui TH; Britikova EV; Britikov VV; Bocharov EV; Usanov SA; Phan VC; Le TBT
Mol Biol Rep; 2024 Jan; 51(1):130. PubMed ID: 38236367
[TBL] [Abstract][Full Text] [Related]
18. Expression, purification, and biological characterization of the amino-terminal fragment of urokinase in Pichia pastoris.
Li J; Lin Y; Zhuang H; Hua ZC
J Microbiol Biotechnol; 2013 Sep; 23(9):1197-205. PubMed ID: 23751561
[TBL] [Abstract][Full Text] [Related]
19. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
20. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
